Tillkännagivande • Jul 10
Tatva Chintan Pharma Chem Limited to Report Q1, 2027 Results on Jul 17, 2026 Tatva Chintan Pharma Chem Limited announced that they will report Q1, 2027 results on Jul 17, 2026 Reported Earnings • May 18
Full year 2026 earnings: EPS misses analyst expectations Full year 2026 results: EPS: ₹17.98 (up from ₹2.44 in FY 2025). Revenue: ₹5.09b (up 33% from FY 2025). Net income: ₹420.5m (up ₹363.4m from FY 2025). Profit margin: 8.3% (up from 1.5% in FY 2025). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 4.1%. Revenue is forecast to grow 20% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings. Buy Or Sell Opportunity • May 15
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 9.5% to ₹1,312. The fair value is estimated to be ₹1,081, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 44%. Revenue is forecast to grow by 53% in 2 years. Earnings are forecast to grow by 152% in the next 2 years. Tillkännagivande • May 06
Tatva Chintan Pharma Chem Limited to Report Q4, 2026 Results on May 16, 2026 Tatva Chintan Pharma Chem Limited announced that they will report Q4, 2026 results at 12:08 PM, Indian Standard Time on May 16, 2026 Buy Or Sell Opportunity • Apr 15
Now 21% overvalued Over the last 90 days, the stock has fallen 8.2% to ₹1,246. The fair value is estimated to be ₹1,030, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 44%. Revenue is forecast to grow by 53% in 2 years. Earnings are forecast to grow by 152% in the next 2 years. Buy Or Sell Opportunity • Feb 02
Now 25% overvalued Over the last 90 days, the stock has fallen 25% to ₹1,145. The fair value is estimated to be ₹912, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has declined by 44%. Revenue is forecast to grow by 53% in 2 years. Earnings are forecast to grow by 152% in the next 2 years. Reported Earnings • Jan 22
Third quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2026 results: EPS: ₹6.49 (up from ₹0.06 in 3Q 2025). Revenue: ₹1.31b (up 53% from 3Q 2025). Net income: ₹151.7m (up ₹150.3m from 3Q 2025). Profit margin: 12% (up from 0.2% in 3Q 2025). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 3.5%. Earnings per share (EPS) exceeded analyst estimates by 44%. Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings. Tillkännagivande • Jan 12
Tatva Chintan Pharma Chem Limited to Report Q3, 2026 Results on Jan 21, 2026 Tatva Chintan Pharma Chem Limited announced that they will report Q3, 2026 results on Jan 21, 2026 Price Target Changed • Nov 07
Price target increased by 24% to ₹1,035 Up from ₹834, the current price target is an average from 3 analysts. New target price is 31% below last closing price of ₹1,500. Stock is up 66% over the past year. The company is forecast to post earnings per share of ₹20.15 for next year compared to ₹2.44 last year. Reported Earnings • Nov 01
Second quarter 2026 earnings: EPS and revenues exceed analyst expectations Second quarter 2026 results: EPS: ₹4.24 (up from ₹0.29 loss in 2Q 2025). Revenue: ₹1.25b (up 49% from 2Q 2025). Net income: ₹99.2m (up ₹105.8m from 2Q 2025). Profit margin: 8.0% (up from net loss in 2Q 2025). The move to profitability was driven by higher revenue. Revenue exceeded analyst estimates by 1.2%. Earnings per share (EPS) also surpassed analyst estimates by 6.0%. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 56% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings. Tillkännagivande • Oct 18
Tatva Chintan Pharma Chem Limited to Report Q2, 2026 Results on Oct 31, 2025 Tatva Chintan Pharma Chem Limited announced that they will report Q2, 2026 results on Oct 31, 2025 Declared Dividend • Aug 28
Dividend reduced to ₹1.00 Dividend of ₹1.00 is 50% lower than last year. Ex-date: 12th September 2025 Payment date: 26th October 2025 Dividend yield will be 0.09%, which is lower than the industry average of 0.8%. Tillkännagivande • Aug 19
Tatva Chintan Pharma Chem Limited, Annual General Meeting, Sep 26, 2025 Tatva Chintan Pharma Chem Limited, Annual General Meeting, Sep 26, 2025, at 16:00 Indian Standard Time. Price Target Changed • Jul 29
Price target increased by 15% to ₹834 Up from ₹724, the current price target is an average from 3 analysts. New target price is 27% below last closing price of ₹1,146. Stock is up 15% over the past year. The company is forecast to post earnings per share of ₹21.15 for next year compared to ₹2.44 last year. New Risk • Jul 25
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.0% average weekly change). Minor Risk Profit margins are more than 30% lower than last year (2.3% net profit margin). Reported Earnings • Jul 25
First quarter 2026 earnings: EPS exceeds analyst expectations while revenues lag behind First quarter 2026 results: EPS: ₹2.19 (down from ₹2.23 in 1Q 2025). Revenue: ₹1.11b (up 4.8% from 1Q 2025). Net income: ₹51.3m (down 1.5% from 1Q 2025). Profit margin: 4.6% (down from 4.9% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 3.7%. Earnings per share (EPS) exceeded analyst estimates by 9.5%. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has only fallen by 21% per year, which means it has not declined as severely as earnings. Tillkännagivande • Jul 17
Tatva Chintan Pharma Chem Limited to Report Q1, 2026 Results on Jul 24, 2025 Tatva Chintan Pharma Chem Limited announced that they will report Q1, 2026 results on Jul 24, 2025 New Risk • Jul 04
New major risk - Revenue and earnings growth Earnings have declined by 27% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 27% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.2% average weekly change). Profit margins are more than 30% lower than last year (1.5% net profit margin). New Risk • May 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Profit margins are more than 30% lower than last year (1.5% net profit margin). Price Target Changed • May 13
Price target decreased by 8.8% to ₹1,024 Down from ₹1,123, the current price target is an average from 4 analysts. New target price is 34% above last closing price of ₹764. Stock is down 30% over the past year. The company is forecast to post earnings per share of ₹6.20 for next year compared to ₹2.44 last year. Price Target Changed • May 06
Price target decreased by 7.3% to ₹1,078 Down from ₹1,162, the current price target is an average from 4 analysts. New target price is 42% above last closing price of ₹760. Stock is down 37% over the past year. The company is forecast to post earnings per share of ₹6.20 for next year compared to ₹2.44 last year. Reported Earnings • May 05
Full year 2025 earnings: EPS misses analyst expectations Full year 2025 results: EPS: ₹2.44 (down from ₹13.26 in FY 2024). Revenue: ₹3.85b (down 2.2% from FY 2024). Net income: ₹57.1m (down 81% from FY 2024). Profit margin: 1.5% (down from 7.7% in FY 2024). The decrease in margin was primarily driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 37%. Revenue is forecast to grow 25% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 61% per year but the company’s share price has only fallen by 31% per year, which means it has not declined as severely as earnings. New Risk • May 04
New major risk - Revenue and earnings growth Earnings have declined by 24% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 24% per year over the past 5 years. Minor Risk Profit margins are more than 30% lower than last year (3.8% net profit margin). Tillkännagivande • Apr 25
Tatva Chintan Pharma Chem Limited to Report Q4, 2025 Results on May 02, 2025 Tatva Chintan Pharma Chem Limited announced that they will report Q4, 2025 results on May 02, 2025 Reported Earnings • Jan 29
Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2025 results: EPS: ₹0.06 (down from ₹1.48 in 3Q 2024). Revenue: ₹859.4m (up 2.1% from 3Q 2024). Net income: ₹1.38m (down 96% from 3Q 2024). Profit margin: 0.2% (down from 4.1% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue missed analyst estimates by 1.6%. Earnings per share (EPS) exceeded analyst estimates. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings. Tillkännagivande • Jan 17
Tatva Chintan Pharma Chem Limited to Report Nine Months, 2025 Results on Jan 28, 2025 Tatva Chintan Pharma Chem Limited announced that they will report nine months, 2025 results on Jan 28, 2025 Reported Earnings • Oct 26
Second quarter 2025 earnings: EPS and revenues miss analyst expectations Second quarter 2025 results: ₹0.29 loss per share (down from ₹3.43 profit in 2Q 2024). Revenue: ₹838.7m (down 13% from 2Q 2024). Net loss: ₹6.64m (down 109% from profit in 2Q 2024). Revenue missed analyst estimates by 19%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 29% per year, which means it has not declined as severely as earnings. Tillkännagivande • Oct 16
Tatva Chintan Pharma Chem Limited to Report Q2, 2025 Results on Oct 25, 2024 Tatva Chintan Pharma Chem Limited announced that they will report Q2, 2025 results on Oct 25, 2024 Declared Dividend • Aug 28
Dividend of ₹2.00 announced Dividend of ₹2.00 is the same as last year. Ex-date: 6th September 2024 Payment date: 20th October 2024 Dividend yield will be 0.2%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (15% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has not increased over the past 2 years but payments have been stable during that time. EPS is expected to grow by 207% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Tillkännagivande • Aug 19
Tatva Chintan Pharma Chem Limited, Annual General Meeting, Sep 20, 2024 Tatva Chintan Pharma Chem Limited, Annual General Meeting, Sep 20, 2024, at 16:00 Indian Standard Time. Price Target Changed • Jul 26
Price target decreased by 15% to ₹1,417 Down from ₹1,674, the current price target is an average from 4 analysts. New target price is 42% above last closing price of ₹1,000. Stock is down 39% over the past year. The company is forecast to post earnings per share of ₹22.50 for next year compared to ₹13.26 last year. New Risk • Jul 25
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 6.8% Last year net profit margin: 10% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (6.8% net profit margin). Shareholders have been diluted in the past year (5.5% increase in shares outstanding). Reported Earnings • Jul 25
First quarter 2025 earnings released: EPS: ₹2.23 (vs ₹4.29 in 1Q 2024) First quarter 2025 results: EPS: ₹2.23 (down from ₹4.29 in 1Q 2024). Revenue: ₹1.05b (down 7.8% from 1Q 2024). Net income: ₹52.1m (down 45% from 1Q 2024). Profit margin: 4.9% (down from 8.3% in 1Q 2024). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Chemicals industry in India. Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has only fallen by 25% per year, which means it has not declined as severely as earnings. Tillkännagivande • Jul 16
Tatva Chintan Pharma Chem Limited to Report Q1, 2025 Results on Jul 24, 2024 Tatva Chintan Pharma Chem Limited announced that they will report Q1, 2025 results on Jul 24, 2024 Price Target Changed • Jun 21
Price target decreased by 7.4% to ₹1,608 Down from ₹1,736, the current price target is an average from 4 analysts. New target price is 45% above last closing price of ₹1,112. Stock is down 38% over the past year. The company is forecast to post earnings per share of ₹29.63 for next year compared to ₹13.26 last year. Reported Earnings • May 04
Full year 2024 earnings: EPS and revenues miss analyst expectations Full year 2024 results: EPS: ₹13.26 (down from ₹20.52 in FY 2023). Revenue: ₹4.01b (down 5.3% from FY 2023). Net income: ₹303.5m (down 33% from FY 2023). Profit margin: 7.6% (down from 11% in FY 2023). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 3.1%. Earnings per share (EPS) also missed analyst estimates by 8.1%. Revenue is forecast to grow 37% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Chemicals industry in India. Tillkännagivande • Apr 26
Tatva Chintan Pharma Chem Limited to Report Q4, 2024 Results on May 03, 2024 Tatva Chintan Pharma Chem Limited announced that they will report Q4, 2024 results on May 03, 2024 Valuation Update With 7 Day Price Move • Apr 04
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹1,245, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 29x in the Chemicals industry in India. Total loss to shareholders of 25% over the past year. Board Change • Mar 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 3 highly experienced directors. Non Executive Independent Director Manher Desai was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Price Target Changed • Jan 23
Price target decreased by 8.1% to ₹1,698 Down from ₹1,847, the current price target is an average from 4 analysts. New target price is 24% above last closing price of ₹1,368. Stock is down 37% over the past year. The company is forecast to post earnings per share of ₹19.90 for next year compared to ₹20.52 last year. Reported Earnings • Jan 21
Third quarter 2024 earnings: EPS and revenues miss analyst expectations Third quarter 2024 results: EPS: ₹1.48 (down from ₹5.24 in 3Q 2023). Revenue: ₹854.2m (down 29% from 3Q 2023). Net income: ₹34.6m (down 70% from 3Q 2023). Profit margin: 4.0% (down from 9.6% in 3Q 2023). The decrease in margin was driven by lower revenue. Revenue missed analyst estimates by 21%. Earnings per share (EPS) also missed analyst estimates by 73%. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Chemicals industry in India. Tillkännagivande • Jan 11
Tatva Chintan Pharma Chem Limited to Report Q3, 2024 Results on Jan 20, 2024 Tatva Chintan Pharma Chem Limited announced that they will report Q3, 2024 results at 12:08 PM, Indian Standard Time on Jan 20, 2024 Reported Earnings • Nov 04
Second quarter 2024 earnings released: EPS: ₹3.43 (vs ₹3.21 in 2Q 2023) Second quarter 2024 results: EPS: ₹3.43 (up from ₹3.21 in 2Q 2023). Revenue: ₹974.3m (up 8.1% from 2Q 2023). Net income: ₹77.8m (up 9.4% from 2Q 2023). Profit margin: 8.0% (up from 7.9% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Chemicals industry in India. Tillkännagivande • Oct 21
Tatva Chintan Pharma Chem Limited to Report Q2, 2024 Results on Nov 02, 2023 Tatva Chintan Pharma Chem Limited announced that they will report Q2, 2024 results on Nov 02, 2023 Upcoming Dividend • Sep 01
Upcoming dividend of ₹2.00 per share at 0.1% yield Eligible shareholders must have bought the stock before 08 September 2023. Payment date: 22 October 2023. Payout ratio is a comfortable 9.7% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of Indian dividend payers (1.4%). Lower than average of industry peers (0.8%). New Risk • Aug 31
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (10% net profit margin). Shareholders have been diluted in the past year (5.5% increase in shares outstanding). Tillkännagivande • Aug 18
Tatva Chintan Pharma Chem Limited, Annual General Meeting, Sep 22, 2023 Tatva Chintan Pharma Chem Limited, Annual General Meeting, Sep 22, 2023, at 16:00 Indian Standard Time. Reported Earnings • Aug 10
First quarter 2024 earnings released: EPS: ₹4.29 (vs ₹4.42 in 1Q 2023) First quarter 2024 results: EPS: ₹4.29 (down from ₹4.42 in 1Q 2023). Revenue: ₹1.14b (up 29% from 1Q 2023). Net income: ₹95.0m (down 3.0% from 1Q 2023). Profit margin: 8.3% (down from 11% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Chemicals industry in India. Tillkännagivande • Jul 29
Tatva Chintan Pharma Chem Limited to Report Q1, 2024 Results on Aug 04, 2023 Tatva Chintan Pharma Chem Limited announced that they will report Q1, 2024 results on Aug 04, 2023 Price Target Changed • May 08
Price target decreased by 11% to ₹2,312 Down from ₹2,609, the current price target is an average from 3 analysts. New target price is 39% above last closing price of ₹1,669. Stock is down 22% over the past year. The company is forecast to post earnings per share of ₹34.60 for next year compared to ₹20.52 last year. Reported Earnings • May 07
Full year 2023 earnings: EPS and revenues miss analyst expectations Full year 2023 results: EPS: ₹20.52 (down from ₹44.59 in FY 2022). Revenue: ₹4.29b (down 1.0% from FY 2022). Net income: ₹454.9m (down 53% from FY 2022). Profit margin: 11% (down from 22% in FY 2022). Revenue missed analyst estimates by 1.4%. Earnings per share (EPS) also missed analyst estimates by 3.4%. Revenue is forecast to grow 30% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in India. Tillkännagivande • May 06
Tatva Chintan Pharma Chem Limited Recommends Final Dividend for the Financial Year 2022-23 Tatva Chintan Pharma Chem Limited announced that at its Board Meeting held on May 5, 2023, the Board Recommended a Final Dividend of INR 2/- (20%) per equity share of INR 10/-each fully paid (subject to deduction of tax, if any) on the equity share capital of INR 22,16,50,620/- (2,21,65,062 equity shares of INR 10/- each) for the financial year 2022-23. This shall be paid subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company. Buying Opportunity • Feb 27
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 15%. The fair value is estimated to be ₹2,378, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 7.1%. Revenue is forecast to grow by 95% in 2 years. Earnings is forecast to grow by 237% in the next 2 years. Reported Earnings • Jan 25
Third quarter 2023 earnings released: EPS: ₹5.24 (vs ₹10.29 in 3Q 2022) Third quarter 2023 results: EPS: ₹5.24 (down from ₹10.29 in 3Q 2022). Revenue: ₹1.22b (up 17% from 3Q 2022). Net income: ₹116.2m (down 49% from 3Q 2022). Profit margin: 9.5% (down from 22% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Chemicals industry in India. Tillkännagivande • Jan 14
Tatva Chintan Pharma Chem Limited to Report Q3, 2023 Results on Jan 24, 2023 Tatva Chintan Pharma Chem Limited announced that they will report Q3, 2023 results on Jan 24, 2023 Reported Earnings • Nov 09
Second quarter 2023 earnings: EPS misses analyst expectations Second quarter 2023 results: EPS: ₹3.21 (down from ₹15.02 in 2Q 2022). Revenue: ₹900.9m (down 27% from 2Q 2022). Net income: ₹71.1m (down 78% from 2Q 2022). Profit margin: 7.9% (down from 26% in 2Q 2022). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 27%. Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Chemicals industry in India. Major Estimate Revision • Nov 07
Consensus revenue estimates fall by 19% The consensus outlook for revenues in 2023 has deteriorated. 2023 revenue forecast decreased from ₹5.21b to ₹4.23b. EPS estimate fell from ₹40.47 to ₹31.80 per share. Net income forecast to grow 12% next year vs 20% growth forecast for Chemicals industry in India. Consensus price target of ₹2,577 unchanged from last update. Share price rose 3.5% to ₹2,486 over the past week. Tillkännagivande • Oct 21
Tatva Chintan Pharma Chem Limited to Report Q2, 2023 Results on Nov 04, 2022 Tatva Chintan Pharma Chem Limited announced that they will report Q2, 2023 results on Nov 04, 2022 Tillkännagivande • Aug 17
Tatva Chintan Pharma Chem Limited, Annual General Meeting, Sep 27, 2022 Tatva Chintan Pharma Chem Limited, Annual General Meeting, Sep 27, 2022, at 16:00 Indian Standard Time. Major Estimate Revision • Aug 01
Consensus forecasts updated The consensus outlook for 2023 has been updated. 2023 EPS estimate fell from ₹47.60 to ₹40.90 per share. Revenue forecast steady at ₹5.20b. Net income forecast to grow 25% next year vs 23% growth forecast for Chemicals industry in India. Consensus price target down from ₹2,734 to ₹2,602. Share price fell 2.7% to ₹2,300 over the past week. Reported Earnings • Jul 26
First quarter 2023 earnings released: EPS: ₹4.42 (vs ₹11.52 in 1Q 2022) First quarter 2023 results: EPS: ₹4.42 (down from ₹11.52 in 1Q 2022). Revenue: ₹902.3m (down 16% from 1Q 2022). Net income: ₹98.0m (down 58% from 1Q 2022). Profit margin: 11% (down from 22% in 1Q 2022). The decrease in margin was driven by lower revenue. Over the next year, revenue is forecast to grow 38%, compared to a 17% growth forecast for the industry in India. Reported Earnings • Apr 27
Full year 2022 earnings: EPS and revenues miss analyst expectations Full year 2022 results: EPS: ₹44.59 (up from ₹26.02 in FY 2021). Revenue: ₹4.34b (up 44% from FY 2021). Net income: ₹958.7m (up 83% from FY 2021). Profit margin: 22% (up from 17% in FY 2021). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 3.7%. Earnings per share (EPS) also missed analyst estimates by 1.9%. Over the next year, revenue is forecast to grow 21%, compared to a 21% growth forecast for the industry in India. Tillkännagivande • Apr 26
Tatva Chintan Pharma Chem Limited Recommends Final Dividend for the Financial Year 2021-22 Tatva Chintan Pharma Chem Limited at its board meeting held on April 25, 2022 Recommended a Final Dividend of INR 2 (20%) per equity share of INR 10 each fully paid (subject to deduction of tax, if any) on the equity share capital of INR 221,650,620 for the financial year 2021-22. This shall be paid subject to the approval of the shareholders at the upcoming Annual General Meeting of the Company. Reported Earnings • Jan 19
Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint Third quarter 2022 results: EPS: ₹10.29 (down from ₹10.51 in 3Q 2021). Revenue: ₹1.05b (down 3.7% from 3Q 2021). Net income: ₹228.1m (up 8.0% from 3Q 2021). Profit margin: 22% (up from 19% in 3Q 2021). The increase in margin was driven by lower expenses. Revenue missed analyst estimates by 12%. Over the next year, revenue is forecast to grow 20%, compared to a 20% growth forecast for the industry in India. Valuation Update With 7 Day Price Move • Oct 30
Investor sentiment improved over the past week After last week's 18% share price gain to ₹2,506, the stock trades at a forward P/E ratio of 51x. Average forward P/E is 31x in the Chemicals industry in India. Simply Wall St's valuation model estimates the intrinsic value at ₹4,504 per share. Reported Earnings • Oct 25
Second quarter 2022 earnings released: EPS ₹15.02 (vs ₹10.51 in 2Q 2021) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: ₹1.24b (up 14% from 2Q 2021). Net income: ₹324.1m (up 54% from 2Q 2021). Profit margin: 26% (up from 19% in 2Q 2021). The increase in margin was driven by higher revenue. Executive Departure • Aug 31
Chief Financial Officer Mahesh Tanna has left the company During their tenure, earnings grew by 75% annually compared to the industry average of 45%. We don't have any record of a personal shareholding under Mahesh's name. A total of 2 executives have left over the last 12 months. 
